The current relevance and use of prednisone in rheumatoid arthritis

References

• Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 2010;62(6):1576-82
   PubMed Web of Science ®Google Scholar
• Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2nd edition. Oxford University Press; New York: 2001
   Google Scholar
• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63(3):633-9
   PubMed Web of Science ®Google Scholar
• Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39(1):115-24
   PubMed Web of Science ®Google Scholar
• Lavagno L, Gunella G, Bardelli C, et al. Anti-inflammatory drugs and tumor necrosis factor-alpha production from monocytes: role of transcription factor NF-kappa B and implication for rheumatoid arthritis therapy. Eur J Pharmacol 2004;501(1-3):199-208
   PubMedGoogle Scholar
• McDevitt H, Munson S, Ettinger R, et al. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002;4(Suppl 3):S141-52
   PubMedGoogle Scholar
• Meusch U, Rossol M, Baerwald C, et al. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 2009;60(9):2612-21
   PubMedGoogle Scholar
• Rossol M, Kraus S, Pierer M, et al. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012;64(3):671-7
   PubMedGoogle Scholar
• Krasselt M, Baerwald C, Wagner U, et al. CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther 2013;15(5):R139
   PubMedGoogle Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-81
   PubMed Web of Science ®Google Scholar
• Berglin E, Dahlqvist SR. Comparison of the 1987 ACR and 2010 ACR/EULAR classification criteria for rheumatoid arthritis in clinical practice: a prospective cohort study. Scand J Rheumatol 2013;42(5):362-8
   PubMed Web of Science ®Google Scholar
• Asare K. Diagnosis and treatment of adrenal insufficiency in the critically ill patient. Pharmacotherapy 2007;27(11):1512-28
   PubMedGoogle Scholar
• Jacobs JW, Bijlsma JW. In: Firestein GS, Kelley WN, editors. Glucocorticoid therapy, in Kelley’s textbook of rheumatology. Elsevier W.B. Saunders; Philadelphia: 2013. p. 894-916
   Google Scholar
• Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic) 1950;85(4):545-666
   PubMedGoogle Scholar
• Arvidson NG, Gudbjornsson B, Elfman L, et al. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994;53(8):521-4
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005;353(16):1711-23
   PubMed Web of Science ®Google Scholar
• Cutolo M, Villaggio B, Otsa K, et al. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease’s symptoms. Autoimmun Rev 2005;4(8):497-502
   PubMed Web of Science ®Google Scholar
• Cutolo M, Straub RH, Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis 2008;67(7):905-8
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007;56(2):399-408
   PubMed Web of Science ®Google Scholar
• Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997;56(1):27-31
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371(9608):205-14
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Clarke L, Hunt LP, et al. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann N Y Acad Sci 2010;1193:127-33
   PubMed Web of Science ®Google Scholar
• Cutolo M. Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2012;24(3):312-18
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013;72(2):204-10
   PubMed Web of Science ®Google Scholar
• Herzog HL, Nobile A, Tolksdorf S, et al. New antiarthritic steroids. Science 1955;121(3136):176
   PubMedGoogle Scholar
• Cohen A, Turner RF, Kanenson WL, et al. Prolonged treatment of rheumatoid arthritis with prednisone (meticorten). J Am Med Assoc 1957;165(3):225-8
   PubMedGoogle Scholar
• Davis M, Williams R, Chakraborty J, et al. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Br J Clin Pharmacol 1978;5(6):501-5
   PubMedGoogle Scholar
• Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002;71(1):9-15
   PubMed Web of Science ®Google Scholar
• Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998;217(4):420-34
   PubMed Web of Science ®Google Scholar
• Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008;4(10):525-33
   PubMedGoogle Scholar
• Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94(6):557-72
   PubMed Web of Science ®Google Scholar
• Spies CM, Bijlsma JW, Burmester GR, et al. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 2010;10(3):302-7
   PubMedGoogle Scholar
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011;335(1):2-13
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002;67(6):529-34
   PubMed Web of Science ®Google Scholar
• Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61(8):718-22
   PubMed Web of Science ®Google Scholar
• Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96(1):23-43
   PubMed Web of Science ®Google Scholar
• Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101(1):227-32
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR. Glucocorticoids. In: Klippel JH, et al. editors. Primer on the rheumatic diseases. Springer; New York: 2008. p. 644-50
   Google Scholar
• Barth J, Mollmann HW, Wagner T, et al. [Problems of equivalency points during therapy with glucocorticoids. A comparison of the clinical pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone]. Dtsch Med Wochenschr 1994;119(48):1671-6
   PubMedGoogle Scholar
• Feher T, Koref O, Tanko A, et al. Metabolism of a prednisolone compound in human under normal and pathological conditions. Arzneimittelforschung 1975;25(8):1314-17
   PubMedGoogle Scholar
• Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 1981;9(4):389-417
   PubMedGoogle Scholar
• Pickup ME. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1979;4(2):111-28
   PubMedGoogle Scholar
• Cutolo M, Iaccarino L, Doria A, et al. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol 2013;31(4):498-505
   PubMed Web of Science ®Google Scholar
• Alten R, Doring G, Cutolo M, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol 2010;37(10):2025-31
   PubMed Web of Science ®Google Scholar
• Derendorf H, Ruebsamen K, Clarke L, et al. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol 2013;53(3):326-33
   PubMed Web of Science ®Google Scholar
• Dunlop W, Iqbal I, Khan I, et al. Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. Clinicoecon Outcomes Res 2013;5:555-64
   PubMedGoogle Scholar
• Boers M, Buttgereit F. A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2013;52(8):1435-7
   PubMedGoogle Scholar
• Pincus T, Swearingen CJ, Luta G, et al. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009;68(11):1715-20
   PubMedGoogle Scholar
• Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012;14(3):R112
   PubMed Web of Science ®Google Scholar
• den Uyl D, Ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Hafstrom I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009;68(4):508-13
   PubMed Web of Science ®Google Scholar
• Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52(11):3360-70
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156(5):329-39
   PubMed Web of Science ®Google Scholar
• van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136(1):1-12
   PubMed Web of Science ®Google Scholar
• Jacobs JW, van Everdingen AA, Verstappen SM, et al. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006;54(5):1422-8
   PubMedGoogle Scholar
• Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(11):3371-80
   PubMed Web of Science ®Google Scholar
• Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66(11):1491-6
   PubMed Web of Science ®Google Scholar
• Caporali R, Scire CA, Todoerti M, et al. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol 2013;31(4 Suppl 78):S9-13
   PubMed Web of Science ®Google Scholar
• Wright V, Amos R. Do drugs change the course of rheumatoid arthritis? Br Med J 1980;280(6219):964-6
   PubMedGoogle Scholar
• Kirwan JR, Currey HL. Rheumatoid arthritis: disease-modifying antirheumatic drugs. Clin Rheum Dis 1983;9(3):581-99
   PubMedGoogle Scholar
• Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69(6):995-1003
   PubMedGoogle Scholar
• Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62(10):2852-63
   PubMed Web of Science ®Google Scholar
• Malysheva OA, Wahle M, Wagner U, et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol 2008;35(6):979-85
   PubMedGoogle Scholar
• Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65(3):285-93
   PubMed Web of Science ®Google Scholar
• Da Silva JA. Safety of glucocorticoids - clinical trials. Clin Exp Rheumatol 2011;29(5 Suppl 68):S99-103
   PubMedGoogle Scholar
• Hwang YG, Saag K. The safety of low-dose glucocorticoids in rheumatic diseases. Clin Exp Rheumatol 2011;29(5 Suppl 68):S104-12
   PubMedGoogle Scholar
• Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009;68(12):1833-8
   PubMedGoogle Scholar
• Engvall IL, Svensson B, Tengstrand B, et al. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 2008;10(6):R128
   PubMedGoogle Scholar
• Keller C, Hafstrom I, Svensson B, et al. Bone mineral density in women and men with early rheumatoid arthritis. Scand J Rheumatol 2001;30(4):213-20
   PubMedGoogle Scholar
• Engvall IL, Brismar K, Hafstrom I, et al. Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study. Scand J Rheumatol 2011;40(3):161-8
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66(12):1560-7
   PubMed Web of Science ®Google Scholar
• Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-13
   PubMed Web of Science ®Google Scholar
• Book C, Karlsson M, Akesson K, et al. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol 2008;37(4):248-54
   PubMed Web of Science ®Google Scholar
• Davis JM III, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;56(3):820-30
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010;69(7):1342-5
   PubMed Web of Science ®Google Scholar
• Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988;85(5):632-8
   PubMedGoogle Scholar
• Garcia-Gomez C, Nolla JM, Valverde J, et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 2008;38(9):686-92
   PubMed Web of Science ®Google Scholar
• Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66(7):958-61
   PubMedGoogle Scholar
• Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther 2006;8(3):R82
   PubMed Web of Science ®Google Scholar
• Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62(9):842-5
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Hallgren R, Mielants H, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004;63(6):688-95
   PubMed Web of Science ®Google Scholar
• Hafstrom I, Rohani M, Deneberg S, et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. J Rheumatol 2007;34(9):1810-16
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69(11):1913-19
   PubMed Web of Science ®Google Scholar
• Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49(4):139-41
   PubMedGoogle Scholar
• Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011;70(11):1887-94
   PubMed Web of Science ®Google Scholar
• Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11(6):954-63
   PubMedGoogle Scholar
• Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010;77(3):246-51
   PubMedGoogle Scholar
• Dixon WG, Kezouh A, Bernatsky S, et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011;70(6):956-60
   PubMed Web of Science ®Google Scholar
• Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65(3):353-61
   PubMed Web of Science ®Google Scholar
• Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• Garbe E, LeLorier J, Boivin JF, et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997;350(9083):979-82
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69(6):1015-21
   PubMed Web of Science ®Google Scholar
• Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012;64(3):639-46
   PubMed Web of Science ®Google Scholar
• Smits NA, Duru N, Bijlsma JW, et al. Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis. Clin Exp Rheumatol 2011;29(5 Suppl 68):S85-92
   PubMedGoogle Scholar
• Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007;275(1-2):98-108
   PubMed Web of Science ®Google Scholar
• Hu X, Du S, Tunca C, et al. The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation. Endocrinology 2011;152(8):3123-34
   PubMed Web of Science ®Google Scholar
• Stock T, Fleishaker D, Wang X, et al. Phase II evaluation of PF-04171327, a dissociated agonist of the glucocorticoid receptor for the treatment of rheumatoid arthritis in patients with an inadequate response to methotrexate, in ACR 2013. Elsevier, San Diego, USA; 2013
   Google Scholar
• Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996;17(3):245-61
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000;130(2):289-98
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Brand MD, Muller M. ConA induced changes in energy metabolism of rat thymocytes. Biosci Rep 1992;12(2):109-14
   PubMedGoogle Scholar
• Buttgereit F, Brand MD, Muller M. Effects of methylprednisolone on the energy metabolism of quiescent and ConA-stimulated thymocytes of the rat. Biosci Rep 1993;13(1):41-52
   PubMedGoogle Scholar
• Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998;41(5):761-7
   PubMedGoogle Scholar
• Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 2000;21(4):192-9
   PubMedGoogle Scholar
• Schmid D, Burmester GR, Tripmacher R, et al. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep 2000;20(4):289-302
   PubMed Web of Science ®Google Scholar
• Chen HC, Farese RV. Steroid hormones: interactions with membrane-bound receptors. Curr Biol 1999;9(13):R478-81
   PubMed Web of Science ®Google Scholar
• Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991;252(5014):1848-51
   PubMed Web of Science ®Google Scholar
• Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004;18(1):70-80
   PubMed Web of Science ®Google Scholar
• Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 2006;246(1-2):142-6
   PubMed Web of Science ®Google Scholar